Product Description
Mechanisms of Action: P-gp Inhibitor,TNF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Chile | Colombia | Dominican Republic | Germany | India | Ireland | Korea | Lebanon | Malaysia | Mexico | Morocco | Pakistan | Peru | Russia | Spain | Taiwan | Thailand | Turkey | United Arab Emirates | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Amen Clinics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Hearing Loss, Sudden|Cognitive Dysfunction|Sleep Apnea, Obstructive|Deafness|Myocardial Ischemia|Coronary Artery Disease|Glaucoma|Type 2 Diabetes|Cognition Disorders|Alzheimer Disease
Phase 3: Memory Disorders|Cognitive Dysfunction|Dementia|Tinnitus
Phase 2: Hearing Loss|Fetal Growth Retardation|Type 2 Diabetes|Insulin Resistance|Raynaud Disease
Phase 1: Coronary Disease|Angina Pectoris
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BEFIT | N/A |
Not yet recruiting |
Ischemic Stroke |
2026-10-01 |
|
GRACE | P4 |
Not yet recruiting |
Cognitive Dysfunction |
2025-12-31 |
|
ChiCTR2200063158 | N/A |
Not yet recruiting |
Unknown |
2024-12-31 |
|
BTCHENT201901 | P4 |
Recruiting |
Sleep Apnea, Obstructive|Deafness|Hearing Loss, Sudden |
2024-12-01 |